On the other hand, several SSAO inhibitors have been reported as limiting fatness in obese rodents [28,29], but never entered clinical anti-obesity development because they belong to the family of hydrazines, endowed with deleterious toxicological effects. This evidence concerns the gene AOC3 and obesity disorder.